KVUE

AI Research

Kenvue-Kimberly Clark Merger Approved with 99% Vote → Expected Close H2 2026, $48.7B Enterprise Value

Kenvue's merger with Kimberly-Clark received shareholder approval with a 99% favorable vote, with the $48.7 billion enterprise value transaction expected to close in the second half of 2026, creating a global consumer health and personal care powerhouse combining brands like Tylenol, Neutrogena, and Huggies. Analyst consensus holds a Hold rating on the combined entity pending deal closure and final terms. Risks include regulatory approval requirements in multiple jurisdictions, integration complexity combining two large consumer goods portfolios, and potential brand rationalization impacts on revenue.